Immunologic profile of highly exposed yet HIV type 1-seronegative men

AIDS Research and Human Retroviruses

Volumn 18, Issue 14, 2002, Pages 1051-1065

  Yang, Otto O ^a   Shodell, Michael ^b   Shearer, Gene M ^a   Grene, Edith ^a   Carrington, Mary ^a   O'Brien, Steve ^a   Price, Charles B ^a   Detels, Roger ^a   Jamieson, Beth D ^c   Giorgi, Janis V ^c   Boscardin, W John ^d   Matud, Jose ^d   Hausner, Mary Ann ^e   Hultin, Lance E ^e   Hultin, Patricia M ^a   Shih, Roger ^b   Ferbas, John ^a   Siegal, Frederick P ^a  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ST VINCENT S HOSPITAL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

ADULT; ARTICLE; CELL ACTIVITY; CELL COUNT; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENOTYPE; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOASSAY; INFECTION RISK; LONG TERM EXPOSURE; MALE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; SERODIAGNOSIS; T LYMPHOCYTE; VIRUS IMMUNITY;

ADULT; AMINO ACID SEQUENCE; CHRONIC DISEASE; CYTOKINES; HIV SERONEGATIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; INTERFERON TYPE II; MALE; PEPTIDES; RECEPTORS, CCR5; RETROVIRIDAE PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VIRUS DISEASES;

EID: 0036392177     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220260235416     Document Type: Article

References (48)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103 -6110.
2. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68: 4650-4655.
3. Ogg GS, Jin X, Bonhoeffer S, et al.: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103 -2106.
4. Harrer T, Harrer E, Kalams SA, et al.: Strong cytotoxic T cells and weak neutralizing antibodies in long-term non-progressing HIV-1 infection. AIDS Res Hum Retroviruses 1996;12:585 -592.
5. Harrer T, Harrer E, Kalams S, et al.: Cytotoxic T lymphocytes in asymptomatic long-term non-progressing HIV-1 infection: Breadth and specificity of the response and relation to in vivo viral quasi-species in a person with prolonged infection and low viral load. J Immunol 1996;156:2616 -2623.
6. Rinaldo C, Huang X-L, Fan Z, et al.: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995;69: 5838-5842.
7. + cells in human immunodeficiency virus type I pathogenesis: Cytolytic and noncytolytic inhibition of viral replication. Adv Immunol 1997;66:273 -311.
8. + T cells. Immunol Today 1996;17:217 -224.
9. + T cell responses associated with control of viremia. Science 1997;278:1447-1450.
10. Rowland-Jones S, Sutton J, Ariyoshi K, et al.: HIV-specific cytotoxic T-cells in HIV-1 exposed but uninfected Gambian women. Nat Med 1995;1:59-64.
11. Rowland-Jones SL, Dong T, Dorrell L, et al.: Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Immunol Lett 1999;66:9-14.
12. De Maria A, Cirillo C, and Moretta L: Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J Infect Dis 1994;170:1296-1299.
13. Rowland-Jones SL, Nixon DF, Aldhous MC, et al.: HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993;341:860-861.
14. Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, and Oksenhendler E: Human immunodeficiency virus (HIV) Nef-specific cytotoxic T lymphocytes in noninfected heterosexual contacts of HIV-infected patients. J Clin Invest 1993;93:1293-1297.
15. Pinto LA, Sullivan J, Berzofsky JA, et al.: Env-specific cytotoxic T lymphocyte responses in HIV seronegative heatlh care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest 1995;96:867-876.
16. Clerici M, Giorgi JV, Chou CC, et al.: Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seroneg-ative homosexual men with recent sexual exposure to HIV-1 [see comments]. J Infect Dis 1992;165:1012-1019.
17. Bienzle D, MacDonald KS, Smaill FM, et al.: Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-1-discordant partners. J Infect Dis 2000;182: 123-132.
18. Detels R, Liu Z, Hennessey K, et al.: Resistance to HIV-1 infection. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1994;7:1263-1269.
19. Liu R, Paxton W, Choe S, et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance in some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
20. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-1862.
21. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, and Rinaldo CR Jr: The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants. Am J Epi-demiol 1987;126:310-318.
22. Imagawa DT, Lee MH, Wolinsky SM, et al.: Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med 1989;320: 1458-1462.
23. Detels R, Phair JP, Saah AJ, et al.: Recent scientific contributions to understanding HIV/AIDS from the Multicenter AIDS Cohort Study. J Epidemiol (Japan) 1992;2:S11-S19.
24. O'Brien TR, Padian NS, Hodge T, Goedert JJ, O'Brien SJ, and Carrington M: CCR-5 genotype and sexual transmission of HIV-1. AIDS 1998;12:444-445.
25. Smith MW, Dean M, Carrington M, Huttley GA, and O'Brien SJ: CCR5-δ32 gene deletion in HIV-1 infected patients. Lancet 1997; 350:741; discussion 742.
26. + T lymphocytes as a biological calibrator. Cytometry 1998;33:123-132.
27. Siegal FP, Lopez C, Fitzgerald PA, et al.: Opportunistic infections in acquired immune deficiency syndrome result from synergistic defects of both the natural and adaptive components of cellular immunity. J Clin Invest 1986;78:115-123.
28. Pross HF, Baines MG, Rubin P, Shragge P, and Patterson MS: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1:51-63.
29. Tary-Lehmann M, Hricik DE, Justice AC, Potter NS, and Heeger PS: Enzyme-linked immunosorbent assay spot detection of interferon-γ and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation 1998;66:219 -224.
30. + lymphocyte activity. J Infect Dis 1995;172:329-339.
31. Westfall PH and Young SS: Resampling-Based Multiple Testing. John Wiley & Sons, New York, 1993.
32. Wagner L, Yang OO, Garcia-Zepeda EA, et al.: β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998;391:908-911.
33. DeMaeyer E and DeMaeyer-Guignard J: Interferons and Other Regulatory Cytokines. John Wiley & Sons, New York, 1988.
34. Pitha PM: Multiple effects of interferon on HIV-1 replication. J In-terferon Res 1991;11:313-318.
35. Siegal FP, Kadowaki N, Shodell M, et al.: The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-1837.
36. Brander C and Goulder PJR: The evolving field of HIV CTL epitope mapping: New approaches to the identification of novel epitopes. In: HIV Molecular Immunology Database (Korber BTM, Brander C, Haynes BF, et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, 2000, pp. I1-I19.
37. + cells is associated with subsequent stable CD41 cell levels. Multicenter AIDS Cohort Study Group. J Infect Dis 1994;170:775-781.
38. Roederer M, Dubs JG, Anderson MT, Raju PA, and Herzenberg LA: CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995;95:2061-2066.
39. Goh WC, Markee J, Akridge RE, et al.: Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J Infect Dis 1991;179:548-557.
40. Bernard NF, Yannakis CM, Lee JS, and Tsoukas CM: Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons. J Infect Dis 1999; 179:538-547.
41. + responses. J Clin Invest 2001;107:341-349.
42. + T cells. Science 1995;270:1811-1815.
43. + cells: Evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997;71:3120-3128.
44. Ferbas JJ, Toso JF, Logar AJ, Navratil JS, and Rinaldo CR Jr: CD41 blood dendritic cells are potent producers of IFN-α in response to in vitro HIV-1 infection. J Immunol 1994;152: 4649-4662.
45. Soumelis V, Scott I, Gheyas F, et al.: Depletion of natural interferon-α producing cells in AIDS patients. Blood 2001 (In press).
46. Cohen OJ, Vaccarezza M, Lam GK, et al.: Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors. J Clin Invest 1997;100: 1581-1589.
47. Taylor JM, Wang Y, Ahdieh L, et al.: Causal pathways for CCR5 genotype and HIV progression. J Acquir Immune Defic Syndr 2000;23:160-171.
48. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-188.